HAS2 and keloid: Future studies should prioritize experimental validation of AMPH/TNFRSF9 in larger cohorts, functional characterization of IL6/HAS2 in keloid models and development of quercetin topical formulations to address the clinical need for safe and effective anti-keloid treatment.